Management is transitioning from monotherapy to a dual-blockade strategy, combining emavusertib with BTK inhibitors to target both BCR and TLR pathways simultaneously. The strategic rationale addresses a critical gap in the current CLL standard of care, where BTKi monotherapy typically only achieves partial responses and leads to chronic treatment dependency. Performance in the AML triplet study demonstrated proof-of-concept for disease clearance, with five of eight evaluable patients achieving MRD co ...